More than three in four heart failure patients (77%) implanted with a Reveal LINQ™ insertable cardiac monitor (ICM) experienced arrhythmias within two years, leading to a high rate of guideline-recommended therapies, according to a new analysis published online today in the Journal of American College of Cardiology (JACC).
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.